Drugs / Corvitol
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00942487 Comparator | Apr 2005 → Dec 2008 | essential hypertension | Berlin-Chemie Menarini | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Corvitol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00942487 ↗ |
| Known as | metoprolol | “Trade-mark: Corvitol (Berlin-Chemie Menarini) INN: metoprolol Dosage and route of administration: 50 mg tablets, b.d. (100 mg/day) for oral administration” NCT00942487 ↗ |
| Route | Oral | “for oral administration” NCT00942487 ↗ |